Clinical Milestones Update: Recent chatter on social media has focused on Zentalis Pharmaceuticals' latest corporate update regarding its Azenosertib development program. Many are highlighting the completion of DENALI Part 2a enrollment and the anticipated dose confirmation in the first half of 2026. There's also buzz about potential topline data by year-end 2026, which has sparked keen interest.
Insider Purchase Buzz: Another hot topic circulating online is the significant insider purchase by a major shareholder group, reportedly acquiring millions of shares at a low price. This move, totaling over $7.7 million as per recent web reports, is being interpreted by some as a strong vote of confidence in the company’s future. Discussions are lively, with many speculating on the implications for the stock’s trajectory.
Note: This discussion summary was generated from an AI condensation of post data.
Zentalis Pharmaceuticals Insider Trading Activity
Zentalis Pharmaceuticals insiders have traded $ZNTL stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ZNTL stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT COMPANY, LP MATRIX sold 7,500,000 shares for an estimated $9,975,000
- GROUP WALTERS purchased 6,459,973 shares for an estimated $7,751,967
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Zentalis Pharmaceuticals Hedge Fund Activity
We have seen 39 institutional investors add shares of Zentalis Pharmaceuticals stock to their portfolio, and 56 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC removed 2,574,287 shares (-74.0%) from their portfolio in Q3 2025, for an estimated $3,887,173
- CITADEL ADVISORS LLC added 1,614,950 shares (+349.3%) to their portfolio in Q3 2025, for an estimated $2,438,574
- OPALEYE MANAGEMENT INC. removed 1,607,750 shares (-83.5%) from their portfolio in Q3 2025, for an estimated $2,427,702
- ALMITAS CAPITAL LLC removed 1,141,944 shares (-71.4%) from their portfolio in Q3 2025, for an estimated $1,724,335
- BANK OF AMERICA CORP /DE/ added 835,466 shares (+117.1%) to their portfolio in Q3 2025, for an estimated $1,261,553
- RENAISSANCE TECHNOLOGIES LLC added 795,802 shares (+52.0%) to their portfolio in Q3 2025, for an estimated $1,201,661
- TYBOURNE CAPITAL MANAGEMENT (HK) LTD removed 516,666 shares (-35.0%) from their portfolio in Q3 2025, for an estimated $780,165
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Zentalis Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $ZNTL recently. We have seen 2 analysts offer price targets for $ZNTL in the last 6 months, with a median target of $4.5.
Here are some recent targets:
- Matthew Harrison from Morgan Stanley set a target price of $4.0 on 11/12/2025
- Derek Archila from Wells Fargo set a target price of $5.0 on 08/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
